Giovanni Paniccia
A5034744662- HIV Research and Treatment
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Virology and Viral Diseases
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- HIV/AIDS drug development and treatment
- Bacteriophages and microbial interactions
- Hepatitis B Virus Studies
Istituto Superiore di Sanità
2009-2021
Istituti Fisioterapici Ospitalieri
2009-2010
San Gallicano Hospital
2009-2010
Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This attributed persistent virus expression reservoirs and cell activation. Of note, CD4+ T cells monocyte-macrophages of virologically-suppressed individuals, there continued multi-spliced transcripts encoding regulatory proteins. Among them, Tat essential for gene either primary infection or reactivation during...
The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and safety of biologically active HIV-1 Tat protein administered 7.5 or 30 μg, given 3 5 times monthly, exploring immunological virological disease biomarkers. study duration 48 weeks, however, vaccinees were followed until last enrolled subject reached weeks. Reported are final data up to 144 weeks follow-up. ISS T-002 conducted in 11...
Tat is a key HIV-1 virulence factor, which plays pivotal roles in virus gene expression, replication, transmission and disease progression. After release, extracellular accumulates tissues exerts effects on both the immune system, promoting activation spreading while disabling host defense. In particular, binds Env spikes particles forming entry complex, favors infection of dendritic cells efficient to T via RGD-binding integrins. also shields CCR5-binding sites rendering ineffective...
Although combined antiretroviral therapy (cART) has saved millions of lives, it is incapable full immune reconstitution and virus eradication. The transactivator transcription (Tat) protein a key human immunodeficiency (HIV) virulence factor required for replication transmission. Tat expressed released extracellularly by infected cells also under cART in this form induces dysregulation, promotes reactivation, entry spreading. Of note, anti-Tat antibodies are rare natural infection and, when...
Introduction: Tat, a key HIV virulence protein, has been targeted for the development of therapeutic vaccine aimed at cART intensification. Results from phase II clinical trials in Italy (ISS T-002) and South Africa T-003) cART-treated patients indicated that Tat vaccination promotes return to immune homeostasis reduces virus reservoir. Here we present data 92 vaccinees enrolled ISS T-002 8-year extended follow-up study EF-UP, ClinicalTrials.gov NCT02118168). Results: Anti-Tat antibodies...
BackgroundLow-level HIV viremia originating from virus reactivation in reservoirs is often present cART treated individuals and represents a persisting source of immune stimulation associated with sub-optimal recovery CD4+ T cells. The HIV-1 Tat protein released the extracellular milieu activates cells latent HIV, leading to production release. However, relation anti-Tat immunity residual viremia, persistent activation T-cell dynamics has not yet been defined.MethodsVolunteers enrolled...